From the Journals

Semaglutide Tested in Alcohol Use Disorder

Randomized trial found improvements in alcohol consumption and metabolic outcomes, with gastrointestinal adverse events more common with treatment

1

Semaglutide reduced heavy drinking days by 41% vs. 26% for placebo.
2

Study involved 108 participants with obesity and alcohol use disorder.
3

Significant reductions in total alcohol consumption were observed.
4

Patients receiving semaglutide had greater metabolic improvements.
5

Common side effects included gastrointestinal issues, mainly nausea.
6

Cognitive Behavioral Therapy was part of the intervention for all.
7

The study's limitations included a single-center design and lack of follow-up after 26 weeks.
8

Caution is advised due to uncertainties in generalizability and long-term effects.